Procter & Gamble donates proprietary "super aspirin" technology to Vanderbilt University

NASHVILLE, TN (November 2, 2000) - The next "super aspirin" may be among a collection of 196 patents and pending patents given today to Vanderbilt University by Cincinnati-based Procter & Gamble (NYSE: PG). P&G's proprietary COX-2 Inhibitor Technology shows promise in improving the safety of medications commonly taken for pain, inflammation, and fever reduction.

Along with the patents, P&G is donating all associated intellectual property. As the sole new owners of the technology, Vanderbilt will benefit from all future revenues after the technology is further developed, tested, and commercialized.

"We are pleased that Vanderbilt's international reputation in the area of eicosanoids (COX products) has been affirmed by this generous gift of intellectual property, and we are excited with the opportunity to develop it into something of clinical value," said Lee E. Limbird, Ph.D., associate vice chancellor for Research.

Procter & Gamble's external consultants identified Vanderbilt as the university that is most uniquely qualified to further develop the COX-2 Inhibitor Technology due to their on-going leadership in COX-2 research. In addition, Vanderbilt's Office of Enterprise Development gives the framework for commercializing the technology.

"We're excited that Vanderbilt will continue to develop and test this significant technology, and that Vanderbilt will benefit both financially and academically from this donation," said P&G's Chief Technology Officer Gil Cloyd. "Best of all, we'll get to see this promising science furthered to improve peoples' lives - even if it will no longer be in P&G hands."

The gift of COX-2 Inhibitor Technology is the sixth in a series of Procter & Gamble technology donations to leading universities and research institutions.

About COX-2 inhibitor technology

COX-2 Inhibitor Technology compounds block the action of an enzyme called cyclooxygenase-2 (COX-2), and like other recently marketed COX-2 inhi

Contact: Leigh MacMillan
Vanderbilt University Medical Center

Page: 1 2 3

Related biology news :

1. Derek R. Lovley receives 2004 Proctor & Gamble Award from American Society for Microbiology
2. UC Santa Barbara donates discovery to OneWorld Health that may speed disease treatment
3. Kimberly-Clark Worldwide donates intellectual property to Rensselaer
4. Dupont donates patents to UCSD
5. Donation valued at $12 million: Hoechst Research & Technology donates cut resistant fiber patents to Clemson University
6. Zengen, Inc. receives patent application approval for proprietary peptide technology
7. CWRU physicists invent "supershielding" for MRI devices
8. Yale digital diagnostic technology is basis of new company, HistoRx Inc.
9. AACR applauds NCI initiative on nanotechnology
10. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
11. New imaging technology at Joslin shown to detect early signs of type 1 diabetes

Post Your Comments:

(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
(Date:7/4/2020)... ... July 03, 2020 , ... ... earn outstanding recognition and multiple awards for not only the products and treatments ... SoME® Skincare and Vivace® Microneedle RF. All the brands built by ABM have ...
(Date:7/1/2020)... ... 2020 , ... Cure Glioblastoma, a registered 501(c)(3) nonprofit research ... adult brain cancer—announced today the appointments of its first Senior Fellows: John Boockvar, ... organization’s initiatives and overall vision. , "Senior Fellows are more than advisors; they ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... R3 Stem ... injections for only $3950. With 50 million stem cells total, patients may choose which ... cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical ...
(Date:7/31/2020)... ... , ... eSource has long been touted as the solution to high data ... the reasons it did not take off as quickly as people initially expected, and ... moving towards capturing data electronically for clinical trials and then repurposing it for downstream ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said Matt ... the market and we were pleased that the IFT jury recognized that.” reFRESH™ couples ... a natural way to extend the shelf life and improve the safety of perishable ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
Breaking Biology Technology:
Cached News: